A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis
Status:
Recruiting
Trial end date:
2024-06-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK)
of RO7303509 treatment in participants with systemic sclerosis (SSc) during a
multiple-ascending-dose (MAD) portion of the trial. The MAD stage will consist of a treatment
period of 12 weeks followed by either a safety follow-up period of 9 weeks or continued
treatment in an optional open-label safety extension (OSE) stage of 52 weeks to assess the
long-term safety.